In this article, we will list the 5 Best Penny Stocks to Buy Before They Explode. Please visit 10 Best Penny Stocks to Buy Before They Explode if you would like to see the extended list and the methodology behind it.

5. Ocugen, Inc. (NASDAQ:OCGN)

On May 5, 2026, Ocugen, Inc. (NASDAQ:OCGN) reported Q1 EPS of (6c), versus the consensus estimate of (5c). Revenue totaled $1.53M, versus the consensus estimate of $358,140. Chairman, CEO, and Co-Founder Dr. Shankar Musunuri said the company completed enrollment in two late-stage programs during the first few months of 2026 and is continuing preparations toward initiating its first BLA submission for retinitis pigmentosa and a registration trial for dry AMD later this year. Musunuri also said Ocugen believes it is executing efficiently against its strategic plans, citing productivity levels, recent financing activity, and milestone progress aimed at supporting long-term value creation.

A day earlier, Ocugen, Inc. (NASDAQ:OCGN) announced plans to offer, subject to market conditions and other factors, $115M aggregate principal amount of convertible senior notes due 2034 in a private offering to qualified institutional buyers under Rule 144A of the Securities Act.

Last month, Ocugen, Inc. (NASDAQ:OCGN) announced that dosing was completed ahead of schedule in the Phase 2/3 GARDian3 pivotal confirmatory clinical trial evaluating OCU410ST for Stargardt disease. The company said the trial represents its second late-stage clinical program and added that it plans to submit a BLA for OCU410ST by mid-2027 as part of its broader goal of filing three BLAs by 2028.

Ocugen, Inc. (NASDAQ:OCGN) is a biopharmaceutical company focused on developing and commercializing gene therapies, cell therapies, biologics, and vaccines.

4. Clean Energy Fuels Corp. (NASDAQ:CLNE)

On May 7, 2026, Clean Energy Fuels Corp. (NASDAQ:CLNE) reported Q1 adjusted EPS of (1c), versus the consensus estimate of (3c). Revenue totaled $117.56M, versus the consensus estimate of $97.85M. The company said renewable natural gas volumes continued to recover from last year despite weather-related disruptions affecting dairy RNG production, particularly in the upper Midwest. Management added that operating refinements across the industry are helping improve production consistency, while newer projects such as the East Valley facility in Idaho and the South Fork project in Texas are continuing to ramp up output. Clean Energy Fuels Corp. (NASDAQ:CLNE) also said higher oil and diesel prices following the conflict in Iran have increased interest in its natural gas transportation fuel offerings, which management described as less volatile than diesel. The company added that results during the quarter reflected some benefits from elevated diesel pricing against a relatively stable natural gas commodity backdrop.

On May 4, 2026, Clean Energy Fuels Corp. (NASDAQ:CLNE) announced the expansion of its renewable natural gas fueling network with six new stations across California, New Jersey, Oklahoma, Michigan, and Washington. The stations are positioned along major freight transportation corridors and are intended to support growing adoption of Cummins’ X15N natural gas engine for heavy-duty trucking applications. The company said the new locations expand its network of more than 600 fueling stations across North America, serving transit, refuse, municipal, airport, and trucking fleets.

Last month, Clean Energy Fuels Corp. (NASDAQ:CLNE) announced the appointment of Clay Corbus as President and Chief Executive Officer, effective immediately. Corbus also joined the company’s board of directors, succeeding co-founder Andrew Littlefair, who led the company for 30 years. Littlefair transitioned from the CEO role to serve as a non-employee government relations consultant while remaining on the board.

Clean Energy Fuels Corp. (NASDAQ:CLNE) provides natural gas transportation fuels and fueling solutions for vehicle fleets across the United States and Canada.

3. The Real Brokerage Inc. (NASDAQ:REAX)

On May 8, 2026, B. Riley analyst Naved Khan lowered the firm’s price target on The Real Brokerage Inc. (NASDAQ:REAX) to $7 from $8 while maintaining a Buy rating. The firm said it viewed the company’s Q1 results positively.

On May 7, 2026, The Real Brokerage Inc. (NASDAQ:REAX) reported Q1 EPS of (2c). Revenue totaled $465.6M, versus the consensus estimate of $481.87M. Chairman and CEO Tamir Poleg said the company delivered another quarter of strong growth, with revenue increasing 32% year over year, reflecting continued momentum in its platform and agent value proposition. Poleg also described the planned acquisition of RE/MAX Holdings as a transformative event for both the company and the broader real estate industry.

On April 27, 2026, The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX Holdings, Inc. announced a definitive agreement under which Real will acquire RE/MAX Holdings to create a combined technology-enabled real estate platform called Real REMAX Group. The transaction implies an enterprise value for RE/MAX Holdings of approximately $880M and is expected to be accretive to Real’s earnings and adjusted EBITDA margin within the first full fiscal year after closing, excluding integration-related costs. The companies said the deal combines Real’s AI-driven brokerage platform and proprietary software with the RE/MAX global franchise network spanning more than 120 countries and territories and more than 145,000 agents. The combined company is expected to support more than 180,000 agents globally and generate approximately $2.3B in annual revenue and $157M in adjusted EBITDA on a pro forma 2025 basis before synergies.

The companies also expect approximately $30M in annual run-rate cost savings, primarily from shared services, technology efficiencies, and corporate costs, with most of the savings expected by 2027. Following the transaction, Poleg is expected to serve as Chairman and CEO of Real REMAX Group. The combined company is expected to remain listed on Nasdaq under the ticker REAX and headquartered in Miami, while maintaining significant operations in Denver. The transaction is expected to close in the second half of 2026, subject to shareholder approvals, regulatory clearances, and customary closing conditions.

The Real Brokerage Inc. (NASDAQ:REAX) operates as a real estate technology company in the United States and Canada.

2. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

On May 7, 2026, Pacific Biosciences of California, Inc. (NASDAQ:PACB) reported Q1 EPS of (12c), versus the consensus estimate of (13c). Revenue totaled $37.18M, versus the consensus estimate of $39.98M. President and CEO Christian Henry said the company continued to see increasing clinical adoption of HiFi, contributing to another record quarter for consumables revenue, though instrument revenue, particularly from Vega, came in below expectations. Henry added that PacBio made progress on several initiatives, including the expansion of the SPRQ-Nx beta program following positive early feedback on the new chemistry. Based on those results, the company plans a broader commercial rollout to all Revio customers later this month, which management believes could further support consumables growth and Revio demand. Henry also noted that PacBio was selected by Basecamp Research to support the Trillion Gene Atlas project, which could become the world’s largest and most diverse high-fidelity metagenomic dataset. PacBio sees FY26 revenue of $165M-$175M, versus the consensus estimate of $174.42M.

Last month, Pacific Biosciences of California, Inc. (NASDAQ:PACB) and Lucid Genomics announced that Lucid Genomics joined the PacBio Compatible partner program as a tertiary analysis solution for data generated using PacBio long-read sequencing platforms. Lucid Genomics Founder and CEO Dr. Uira Souto Melo said the designation marks an important milestone for both the company and its users, adding that long-read sequencing continues to unlock genomic regions and patterns that were previously difficult to analyze.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) designs, develops, and manufactures sequencing technologies used to address genetically complex challenges.

1. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

On May 7, 2026, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported Q1 EPS of (19c), versus the consensus estimate of (15c). Revenue totaled $71.43M, versus the consensus estimate of $75.66M. Interim President and Chief Executive Officer Frederick Vogt said the company is accelerating commercial adoption and expansion of Amtagvi following record demand levels. Vogt added that Iovance remains positioned for long-term revenue growth through 2026 while continuing to advance several ongoing and new clinical programs, including its registrational sarcoma trial and recently reported initial data for lifileucel in metastatic serous endometrial cancer. Vogt also said internal manufacturing efficiencies, operational improvements, and cost reduction efforts are expected to support gross margin expansion and future profitability.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) said it expects Q2 revenue of $86M-$88M, versus the consensus estimate of $84.36M. The company also maintained FY26 revenue guidance of $350M-$370M, versus the consensus estimate of $359.68M.

Following the earnings report, Chardan lowered its price target on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) to $14 from $16 while maintaining a Buy rating. The firm said it updated its model to reflect revised launch expectations for Amtagvi.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor-infiltrating lymphocyte cell therapies for metastatic melanoma and other solid tumor cancers.

READ NEXT: 10 AI Stocks with Potential to Rise 1000 Percent and 10 Best AI Pick-and-Shovel Stocks to Buy

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.